A Randomized, Placebo-controlled, Double-blinded, Crossover Trial of Pioglitazone for Severe Asthma

The PPAR-γ agonist, pioglitazone, was associated with significant side effects and did not improve the primary outcome measure of the Juniper Asthma Quality of Life Questionnaire (AQLQ) score in severe asthmatics. We conclude that no further studies should be performed with pioglitazone for severe a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Allergy Clin Immunol
Main Authors: Kaler, Maryann, Barochia, Amisha V., Weir, Nargues A., Cuento, Rosemarie A., Stylianou, Mario, Roth, Mark J., Filie, Armando C., Vaughey, Ellen C., Nathan, Steven D., Levine, Stewart J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5723231/
https://ncbi.nlm.nih.gov/pubmed/28625806
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaci.2017.05.033
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados